Tibotec (Johnson & Johnson Pharmaceutical for Infectious Disease and Vaccine) January 2011 – Present (7 years 1 month)  Responsible for transferring a late stage HCV discovery program from Belgium to China: - Nominated the NME in 2010. - Prepared IB and IND filing in Europe and Asia Pacific region. - Successful FIH in EU and moving forward proof of concept studies in Caucasians and Asians. Processing clinical trials both in EU and AP to access the early readout on PK, safety and efficacy in different populations. Current: Janssen Research & Development, Infectious Diseases ,  Tibotec (Johnson & Johnson Pharmaceutical for Infectious Disease and Vaccine) Tibotec (Johnson & Johnson Pharmaceutical for Infectious Disease and Vaccine) January 2011 – Present (7 years 1 month)  Responsible for transferring a late stage HCV discovery program from Belgium to China: - Nominated the NME in 2010. - Prepared IB and IND filing in Europe and Asia Pacific region. - Successful FIH in EU and moving forward proof of concept studies in Caucasians and Asians. Processing clinical trials both in EU and AP to access the early readout on PK, safety and efficacy in different populations. Current: Janssen Research & Development, Infectious Diseases ,  Tibotec (Johnson & Johnson Pharmaceutical for Infectious Disease and Vaccine)

 HCV replicon high throughput screening campaign, incl. hit identification, profiling and establishment of chemical families for hit to lead medicinal chemistry. Designed and established cellular and biochemical assay development for discovery/validation of HCV replication inhibitors